Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.
Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.
A population-based study included nearly 4000 patients diagnosed with AML from 2000 to 2016 in Denmark.
Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.
This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.
Modifications of ABVD or CHOP were common among elderly patients with cHL and may contribute to their disproportionate excess mortality, signaling a need for less toxic regimens.
In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.
Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.
In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.
Inotuzumab ozogamicin instead of gemcitabine added to R-CVP did not improve OS or PFS, but less toxicity among patients with untreated DLBCL with comorbid conditions.
This analysis focused on the allo-HSCT-related end points in a study of patients with newly diagnosed Ph+ ALL treated with a 2-step dasatinib-containing induction regimen.